EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging

Alfonso Russo, Balázs Örzsik, Nefize Yalin, Ivor Simpson, Prince Nwaubani, Antonello Pinna, Riccardo De Marco, Harriet Sharp, Amy Kartar, Nisha Singh, Nicholas Blockley, Alan John Luke Stone und 6 weitere

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.07.029 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Alfonso Russo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Sussex Partnership NHS Foundatio…. Hauptthemen laut MEDLINE: Bipolar Disorder, Magnetic Resonance Imaging, Methylene Blue. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cerebral mitochondrial and hemodynamic abnormalities have been implicated in Bipolar Disorder pathophysiology, likely contributing to neurometabolic vulnerability-leading to worsen clinical outcomes and mood instability. To investigate neurometabolic vulnerability in patients with BD, we combined multi-modal quantitative MRI assessment of cerebral oxygenation with acute administration of Methylene Blue, a neurometabolic/hemodynamic modulator acting on cerebral mitochondria. METHODS: Fifteen euthymic patients with chronic BD-type 1, and fifteen age/gender-matched healthy controls underwent two separate MRI sessions in a single-blinded randomized cross-over design, each after intravenous infusion of either MB (0.5 mg/kg) or placebo. MRI-based measures of Cerebral Blood Flow and Oxygen Extraction Fraction were integrated to compute Cerebral Metabolic Rate of Oxygen in Frontal Lobe, Anterior Cingulate, and Hippocampus-implicated in BD neurometabolic pathophysiology. Inter-daily variation in mood rating was used to assess mood instability. RESULTS: A decrease in global CBF and CMRO2 was observed after acutely administrating MB to all participants. Greater regional CMRO2 reductions were observed after MB, in patients compared to controls in FL (mean = -14.2 ± 19.5 % versus 2.3 ± 14.8 %), ACC (mean = -14.8 ± 23.7 % versus 2.4 ± 15.7 %). The effects on CMRO2 in those regions were primarily driven by patients with longer disease duration and higher mood instability. LIMITATIONS: Sample size; medications potentially impacting on response to MB. CONCLUSIONS: An altered neurometabolic response to MB, a mitochondrial/hemodynamic modulator, was observed in patients, supporting the hypothesis of vulnerability to neurometabolic stress in BD. Integrating quantitative imaging of cerebral oxygen metabolism with a mitochondrial-targeting pharmacological challenge could provide a novel biomarker of neurometabolic and cerebrovascular pathophysiology in BD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderMagnetic Resonance ImagingMethylene BlueHumansFemaleMaleAdultSingle-Blind MethodNeuroimagingCross-Over StudiesMiddle AgedCerebrovascular CirculationGyrus CinguliBrainHippocampusMitochondria

Stichwörter der Autor:innen

Bipolar disorderCMRO(2)Cerebral blood flowMitochondriaNeuroimagingNeuroprogression

Substanzen

Methylene Blue

Autor:innen und Institutionen

  • Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Sussex Partnership NHS Foundation Trust, Worthing, UK. Electronic address: A.Russo@bsms.ac.uk.
  • Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Radiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • School of Engineering and Informatics, University of Sussex, Falmer, Brighton, UK.
  • Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
  • Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK.

Zitieren

APA

Russo, A., Örzsik, B., Yalin, N., Simpson, I., Nwaubani, P., Pinna, A., De Marco, R., Sharp, H., Kartar, A., Singh, N., Blockley, N., Stone, A. J. L., Turkheimer, F. E., Young, A. H., Cercignani, M., Zelaya, F., Asllani, I., & Colasanti, A. (2024). Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.07.029

Vancouver

Russo A, Örzsik B, Yalin N, Simpson I, Nwaubani P, Pinna A, et al. Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.07.029

BibTeX
@article{Russo2024,
  author = {Russo, Alfonso and Örzsik, Balázs and Yalin, Nefize and Simpson, Ivor and Nwaubani, Prince and Pinna, Antonello and De Marco, Riccardo and Sharp, Harriet and Kartar, Amy and Singh, Nisha and Blockley, Nicholas and Stone, Alan John Luke and Turkheimer, Federico E and Young, Allan H and Cercignani, Mara and Zelaya, Fernando and Asllani, Iris and Colasanti, Alessandro},
  title = {Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.07.029}
}
Kostenlos starten →